Evelo Biosciences bets the microbiome can become a drug platform

A biotechnology company researching and developing therapeutics based on the human microbiome.

Engineered changes to the human microbiome could become a repeatable therapeutic platform across cancer, CNS, autoimmune and metabolic disease.

At least $85M raised in two rounds; the report also cites a $50M Series B and a new SEC filing indicating approximately $47.5M.

Founded in 2014 in Cambridge, Massachusetts, Evelo started from the observation that resident microorganisms affect health and might be manipulated to treat or prevent disease.

Flagship Pioneering led Series A and Series B; Evelo partnered with University of Chicago researchers on microbiome-based cancer work, secured patents, and moved toward trials and commercialization. GV, Celgene, Mayo Clinic Ventures and Alexandria Venture Investors were among the named investors.

Resident microorganisms were increasingly understood as having meaningful effects on health and disease.

One microbiome platform could support programs across oncology, CNS, autoimmune and metabolic indications.

University research, patents and trials offered a way to turn a biological insight into defensible therapeutics.

Flagship Pioneering supplied a venture-studio structure designed to conceive, create and fund first-in-category life-science companies.

A platform bet still needs a narrow therapeutic wedge and evidence linking the biology to clinical progress; a broad disease menu alone does not validate it.

The supplied report leaves Evelo in building mode: it had substantial venture backing, university collaboration, patents and plans to trial and commercialize microbiome therapies, but no finished product outcome is documented in the material.